[{"orgOrder":0,"company":"Spiral Therapeutics","sponsor":"Savoir Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"SPT-2101","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Spiral Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Spiral Therapeutics \/ Savoir Capital","highestDevelopmentStatusID":"6","companyTruncated":"Spiral Therapeutics \/ Savoir Capital"}]

Find Clinical Drug Pipeline Developments & Deals by Spiral Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : SPT-2101 is a sustained-release steroid formulation designed for precise inner ear administration using Spiral's novel delivery procedure. Spiral recently completed enrollment of an open label pilot clinical study of SPT-2101 in 10 patients with Meniere'...

                          Brand Name : SPT-2101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 10, 2023

                          Lead Product(s) : SPT-2101

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase I

                          Sponsor : Savoir Capital

                          Deal Size : $8.2 million

                          Deal Type : Financing

                          blank